Ivan Borrello
Tampa General Hospital · 284 works · 22,031 citations · h-index 59
Top works
- PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
- Lenalidomide plus Dexamethasone for Relapsed Multiple Myeloma in North America
- HLA-Haploidentical Bone Marrow Transplantation for Hematologic Malignancies Using Nonmyeloablative Conditioning and High-Dose, Posttransplantation Cyclophosphamide
- Induction of antigen-specific T cell anergy: An early event in the course of tumor progression
- Demonstration of epidermal growth factor-induced receptor dimerization in living cells using a chemical covalent cross-linking agent.
- Egf binding to its receptor triggers a rapid tyrosine phosphorylation of the erbB‐2 protein in the mammary tumor cell line SK‐BR‐3.
- Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells
- Myeloid suppressor cells in cancer: Recruitment, phenotype, properties, and mechanisms of immune suppression
- Conversion of tumor-specific CD4+ T-cell tolerance to T-cell priming through in vivo ligation of CD40
- Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study
- Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function
- High-Dose Granulocyte-Macrophage Colony-Stimulating Factor-Producing Vaccines Impair the Immune Response through the Recruitment of Myeloid Suppressor Cells
- Myeloid-Derived Suppressor Cells Promote Cross-Tolerance in B-Cell Lymphoma by Expanding Regulatory T Cells
- In vivo blockade of CTLA-4 enhances the priming of responsive T cells but fails to prevent the induction of tumor antigen-specific tolerance
- High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease
- Clonogenic Multiple Myeloma Progenitors, Stem Cell Properties, and Drug Resistance
- Cross-presentation of tumor antigens by bone marrow–derived antigen-presenting cells is the dominant mechanism in the induction of T-cell tolerance during B-cell lymphoma progression
- Nonmyeloablative HLA-Haploidentical Bone Marrow Transplantation with High-Dose Posttransplantation Cyclophosphamide: Effect of HLA Disparity on Outcome
- Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide
- Outcomes of Nonmyeloablative HLA-Haploidentical Blood or Marrow Transplantation With High-Dose Post-Transplantation Cyclophosphamide in Older Adults